A $6 million pre-paid advance agreement, with an initial $1 million advance funded at signing.A $15 million standby equity ...

Q2 2025 Earnings Call Transcript July 29, 2025 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, expectations were $2.03. Operator: Thank you for standing by. Welcome to the Merck ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain ...

A new study from the University of California, San Francisco has upended a long-held assumption in neuroscience about how the ...

The Greater Bay Area International Clinical Trial Institute (GBAICTI) is located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Its mission ...

Genethon gets UK MHRA nod to initiate pivotal phase 3 trial of GNT0004, a low-dose microdystrophin gene therapy for Duchenne muscular dystrophy: Paris, France Wednesday, July 30, ...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed at ...

Decentralized Clinical Trials (DCTs) are transforming how we collect clinical data, but this evolution brings unprecedented challenges in data quality, complexity, and integration.

Phase 3 trial clearance is based on the Phase 1/2 results demonstrating safety and efficacy of the 3x10¹³ vg/kg dose of microdystrophin, which is lower than doses used in other gene therapies for ...

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...